Publicacións en colaboración con investigadores/as de Hospital Universitario de la Princesa (16)

2024

  1. Long-term safety of OnabotulinumtoxinA treatment in chronic migraine patients: a five-year retrospective study

    Frontiers in Neurology , Vol. 15

  2. Migraine treatment consensus document of the Spanish Society of Neurology (SEN), Spanish Society of Family and Community Medicine (SEMFYC), Society of Primary Care Medicine (SEMERGEN) and Spanish Association of Migraine and Headache (AEMICE) on migraine treatment

    Medicina Clinica, Vol. 163, Núm. 4, pp. 208.e1-208.e10

  3. Nueva era terapéutica para el ataque de migraña con los recientemente aprobados anticuerpos monoclonales, ditanes y gepantes

    Revista de neurologia, Vol. 78, Núm. 2, pp. 47-57

  4. Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world

    Journal of neurology, neurosurgery, and psychiatry, Vol. 95, Núm. 10, pp. 927-937

2023

  1. Recomendaciones de consenso para el tratamiento de la prevención de la migraña

    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, Vol. 47, Núm. 6, pp. 246-253

  2. [Translated article] Consensus recommendations on the preventive treatment of migraine

    Farmacia Hospitalaria, Vol. 47, Núm. 6, pp. T246-T253

2022

  1. Calcitonin gene–related peptide in migraine: from pathophysiology to treatment

    Neurologia, Vol. 37, Núm. 5, pp. 390-402

  2. Cutaneous Allodynia in Migraine: A Narrative Review

    Frontiers in Neurology, Vol. 12

2021

  1. Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: Present and future implications

    Neurologia, Vol. 36, Núm. 8, pp. 611-617

2020

  1. Evaluation of the concomitant use of oral preventive treatments and onabotulinumtoxinA in chronic migraine: the PREVENBOX study

    European Journal of Neurology, Vol. 27, Núm. 10, pp. 2102-2108

  2. Evidence of and experience with the use of onabotulinumtoxinA in trigeminal neuralgia and primary headaches other than chronic migraine

    Neurologia, Vol. 35, Núm. 8, pp. 568-578

2019

  1. Evidence and experience with onabotulinumtoxinA in chronic migraine: Recommendations for daily clinical practice

    Neurologia, Vol. 34, Núm. 6, pp. 408-417

2018

  1. Factors associated with poor anticoagulation control with vitamin K antagonists among outpatients attended in Internal Medicine and Neurology. The ALADIN study

    Revista Clinica Espanola, Vol. 218, Núm. 7, pp. 327-335

2017

  1. Clinical profile and satisfaction with anticoagulated treatment in patients with non-valvular atrial fibrillation attended in internal medicine and neurology departments of Spain

    Revista de Neurologia, Vol. 65, Núm. 8, pp. 361-367

2014

  1. Clinical management guidelines for subarachnoid haemorrhage. Diagnosis and treatment

    Neurologia

2013

  1. Cuantificación ultrasonográfica de la estenosis carotídea: Recomendaciones de la Sociedad Española de Neurosonología

    Neurologia